NCT01323244 - A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study | Biotech Hunter

Enrollment

142

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Hepatitis C

Interventions

DRUG

TMC435

Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks

Trial Locations (72)

Unknown

Bakersfield

Los Angeles

San Diego

Englewood

Jacksonville

Orlando

New Orleans

Jackson

Tupelo

Chapel Hill

Cincinnati

Philadelphia

Dallas

Houston

San Antonio

Buenos Aires

Rosario, Santa Fe

Adelaide

Concord

Melbourne

Wentworthville

Woolloongabba

Vienna

Antwerp

Brussels

Ghent

São Paulo

Sofia

Toronto

Montreal

Grenoble

Lyon

Nice Cedex 03 N/A

Paris

Berlin

Frankfurt A. M.

Hamburg

Kiel

Münster

Ulm

Würzburg

Haifa

Safed

Monterrey

Amsterdam

Rotterdam

Auckland

Christchurch

Bydgoszcz

Chorzów

Czeladź

Kielce

Mysłowice

Warsaw

Coimbra

Lisbon

San Juan

Bucharest

Moscow

Saint Petersburg

Samara

Smolensk

Stavropol

Barcelona

Madrid

Seville

Valencia

Donetsk

Kyiv

Vinnitsa

Birmingham

London

All Listed Sponsors

lead

Janssen R&D Ireland

INDUSTRY